niacinamide has been researched along with Peritoneal Neoplasms in 10 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Peritoneal Neoplasms: Tumors or cancer of the PERITONEUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib was administered as 400 mg twice daily on days 1-28 of each 4-week cycle." | 6.76 | Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. ( Bodnar, L; Górnas, M; Szczylik, C, 2011) |
| "Sorafenib is a potent inhibitor of the ras/raf/MEK pathway and also targets VEGFR and cKIT." | 6.75 | A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. ( Crawford, J; Dubey, S; Heinze, R; Jänne, PA; Kindler, HL; Kratzke, R; Krug, L; Pang, H; Vokes, E; Wang, X; Watt, C, 2010) |
| "This trial determined the efficacy and tolerability of sorafenib and weekly topotecan in patients with platinum-resistant ovarian cancer (OC) or primary peritoneal carcinomatosis (PPC)." | 5.15 | Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. ( Callahan, M; Johnson, CS; Jones, T; Matei, D; Perkins, SM; Ramasubbaiah, R; Schilder, J; Sutton, G; Whalen, C, 2011) |
| "Since 2007, sorafenib is the new standard for the first-line treatment of advanced hepatocellular carcinoma (HCC), with proved effectiveness on survival, but no complete response." | 3.76 | Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy? ( Adham, M; Boschetti, G; Cassier, P; Dumortier, J; Hervieu, V; Lombard-Bohas, C; Scoazec, JY; Walter, T, 2010) |
| "This study was designed to evaluate the response and toxicity of sorafenib alone or when combined with carboplatin and paclitaxel in patients with platinum-sensitive, recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (EOC)." | 2.79 | Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer. ( Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ, 2014) |
| "Sorafenib was administered as 400 mg twice daily on days 1-28 of each 4-week cycle." | 2.76 | Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. ( Bodnar, L; Górnas, M; Szczylik, C, 2011) |
| "Sorafenib is a potent inhibitor of the ras/raf/MEK pathway and also targets VEGFR and cKIT." | 2.75 | A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. ( Crawford, J; Dubey, S; Heinze, R; Jänne, PA; Kindler, HL; Kratzke, R; Krug, L; Pang, H; Vokes, E; Wang, X; Watt, C, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schwandt, A | 1 |
| von Gruenigen, VE | 1 |
| Wenham, RM | 1 |
| Frasure, H | 1 |
| Eaton, S | 1 |
| Fusco, N | 1 |
| Fu, P | 1 |
| Wright, JJ | 1 |
| Dowlati, A | 1 |
| Waggoner, S | 1 |
| Dalton, HJ | 1 |
| Fleming, ND | 1 |
| Sun, CC | 1 |
| Bhosale, P | 1 |
| Schmeler, KM | 1 |
| Gershenson, DM | 1 |
| Boschetti, G | 1 |
| Walter, T | 1 |
| Hervieu, V | 1 |
| Cassier, P | 1 |
| Lombard-Bohas, C | 1 |
| Adham, M | 1 |
| Scoazec, JY | 1 |
| Dumortier, J | 1 |
| Metzgeroth, G | 1 |
| Ströbel, P | 1 |
| Baumbusch, T | 1 |
| Reiter, A | 1 |
| Hastka, J | 1 |
| Dubey, S | 1 |
| Jänne, PA | 1 |
| Krug, L | 1 |
| Pang, H | 1 |
| Wang, X | 1 |
| Heinze, R | 1 |
| Watt, C | 1 |
| Crawford, J | 1 |
| Kratzke, R | 1 |
| Vokes, E | 1 |
| Kindler, HL | 1 |
| Matei, D | 2 |
| Sill, MW | 2 |
| Lankes, HA | 2 |
| DeGeest, K | 1 |
| Bristow, RE | 1 |
| Mutch, D | 1 |
| Yamada, SD | 1 |
| Cohn, D | 1 |
| Calvert, V | 1 |
| Farley, J | 1 |
| Petricoin, EF | 1 |
| Birrer, MJ | 1 |
| Bodnar, L | 1 |
| Górnas, M | 1 |
| Szczylik, C | 1 |
| Ramasubbaiah, R | 1 |
| Perkins, SM | 1 |
| Schilder, J | 1 |
| Whalen, C | 1 |
| Johnson, CS | 1 |
| Callahan, M | 1 |
| Jones, T | 1 |
| Sutton, G | 1 |
| Schilder, RJ | 1 |
| Gold, MA | 1 |
| Mannel, RS | 1 |
| Modesitt, SC | 1 |
| Hanjani, P | 1 |
| Bonebrake, AJ | 1 |
| Sood, AK | 1 |
| Godwin, AK | 1 |
| Hu, W | 1 |
| Alpaugh, RK | 1 |
| Maass, H | 1 |
| Hölzel, F | 1 |
| Trobisch, H | 1 |
1 review available for niacinamide and Peritoneal Neoplasms
| Article | Year |
|---|---|
Hepatoid adenocarcinoma - review of the literature illustrated by a rare case originating in the peritoneal cavity.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Biopsy; Diagnosis, Diff | 2010 |
6 trials available for niacinamide and Peritoneal Neoplasms
| Article | Year |
|---|---|
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2014 |
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regulated MAP Kinases; Female; | 2010 |
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Fem | 2011 |
Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Ovarian Epithelial; Disease-Free Survival | 2011 |
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dose-Response Relati | 2011 |
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; DNA, Neoplasm; Fallopian Tube Neoplasms; Female; G | 2013 |
3 other studies available for niacinamide and Peritoneal Neoplasms
| Article | Year |
|---|---|
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors | 2017 |
Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy?
Topics: Adult; alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Be | 2010 |
[The influence of a fractionated x-irradiation on the NAD-content of solid tumors and the host liver].
Topics: Animals; Carcinoma, Ehrlich Tumor; Liver Neoplasms; Mice; NAD; Neoplasm Transplantation; Niacinamide | 1967 |